Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
Holding PSTV?
Track your performance easily
PSTV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $2.67
Previous Close$1.27
Volume71.89K
Average Volume (3M)86.74K
Market Cap
$7.49M
Enterprise Value$6.10M
Total Cash (Recent Filing)$4.79M
Total Debt (Recent Filing)$3.40M
Price to Earnings (P/E)―
Beta2.76
Next Earnings
Feb 20, 2025EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding5,896,333
10 Day Avg. Volume58,322
30 Day Avg. Volume86,742
Standard Deviation0.21
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-1.44
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit1.24
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$10.25Price Target Upside776.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Plus Therapeutics News
PremiumCompany Announcements
Plus Therapeutics Advances Radiotherapeutics in Q3 2024Bulls Say, Bears Say
Bulls Say
Clinical Trials And ResearchThe Phase I/II ReSPECT-GBM trial evaluating Re-186-Obisbemeda for the treatment of recurrent or progressive glioblastoma has completed.
Financial PerformanceThe company reported a net loss of $0.37 per share, which was better than the consensus estimated net loss of $0.56 per share.
Regulatory And ApprovalsRhenium (186Re) obisbemeda was granted orphan drug designation by the FDA for the treatment of breast cancer with LM.
Bears Say
Capital RaisesFuture capital raises are now estimated to occur at significantly lower share prices than previously anticipated.
Financial PerformanceRevenue was $1.3 million, compared with our and consensus estimates of $1.6 - 1.7 million.
Stock PerformanceStock weakness following the data presentation comes from an overreaction to a reported dose-limiting toxicity (hemiplegia).
---
Ownership Overview
12.45% Insiders
1.32% Mutual Funds
9.73% Other Institutional Investors
75.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PSTV FAQ
What was Plus Therapeutics Inc’s price range in the past 12 months?
Plus Therapeutics Inc lowest stock price was $1.12 and its highest was $2.67 in the past 12 months.
What is Plus Therapeutics Inc’s market cap?
Currently, no data Available
When is Plus Therapeutics Inc’s upcoming earnings report date?
Plus Therapeutics Inc’s upcoming earnings report date is Feb 20, 2025 which is in 64 days.
How were Plus Therapeutics Inc’s earnings last quarter?
Plus Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.562 by $0.192.
Is Plus Therapeutics Inc overvalued?
According to Wall Street analysts Plus Therapeutics Inc’s price is currently Undervalued.
Does Plus Therapeutics Inc pay dividends?
Plus Therapeutics Inc does not currently pay dividends.
What is Plus Therapeutics Inc’s EPS estimate?
Plus Therapeutics Inc’s EPS estimate is -$0.4.
How many shares outstanding does Plus Therapeutics Inc have?
Plus Therapeutics Inc has 5,896,333 shares outstanding.
What happened to Plus Therapeutics Inc’s price movement after its last earnings report?
Plus Therapeutics Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.562. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Plus Therapeutics Inc?
Currently, no hedge funds are holding shares in PSTV
---
Plus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.25 (776.07% Upside)
$10.25 (776.07% Upside)
Insider Transactions
Bought Shares
Worth $14.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.45%
Trailing 12-Months
Company Description
Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
---
PSTV Earnings Call
Q3 2024
0:00 / 0:00
---
PSTV Stock 12 Month Forecast
Average Price Target
$10.25
▲(776.07% Upside)
Technical Analysis
Best Analysts Covering PSTV
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-52.54%
reiterated a buy rating 23 days ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -52.54% per trade.
---